This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty. J Vasc Surg 2017; 65: 558–570.

Published: 2nd August 2017

Authors: Candy N, Ng E, Velu R

Conclusion

Ten RCTs were included. Drug-coated balloons significantly reduced the need for further target lesion revascularization after six months (odds ratio 0.24, 95 per cent confidence interval 0.11 to 0.53, P=0.0004), one year (0.28, 0.13 to 0.62, p=0.002) and two years (0.25, 0.1 to 0.61, p=0.002).

Pubmed Link

You may also be interested in

Scientific Surgery

Network meta-analysis of drug-coated balloon angioplasty versus primary nitinol stenting for femoropopliteal atherosclerotic disease. J Vasc Surg 2021; 73: 1802-1810.

Authors: Abdoli S, Mert M, Lee WM, Ochoa CJ, Katz SG

Scientific Surgery

Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 2020; 383: 2538-2546.

Authors: Nordanstig J, James, S, Andersson M, Andersson M, Danielsson P, Gillgren P et al.

Scientific Surgery

Short term success of treatments to salvage thrombosed or failing synthetic arteriovenous grafts in end stage renal disease: a systematic review and network meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg 2019; 58: 921-928

Authors: Nikolopoulos GK, Yiallourou AI, Argyriou C, Bonovas S, Georgiadis GS, Lazarides MK et al.

Scientific Surgery

Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Intervent Radiol 2020; 31: 202-212

Authors: Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Paraskevopoulos I, Karnabatidis D et al.

Scientific Surgery

Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 24: e011245.

Authors: Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D

Scientific Surgery

Infrapopliteal angioplasty of one or more than one artery for critical limb ischaemia: a randomised clinical trial. Eur J Vasc Endovasc Surg 2018; 55: 518-527.

Authors: Biagioni RB, Biagioni LC, Nasser F, Burihan MC, Ingrund JC, Neser A et al.

Scientific Surgery

Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018; 378: 603-614.

Authors: Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S-S et al.

Scientific Surgery

Low-dose paclitaxel–coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease. Circulation. 2017; 135: 2227-2236.

Authors: Schroeder H, Werner M, Meyer D-R, Reimer P, Krüger K, Jaff MR et al.

Scientific Surgery

Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation. 2017; 135: 2218-2226.

Authors: Ott I, Cassese S, Groha P, Steppich B, Hadamitzky M, Ibrahim T et al.

Scientific Surgery

A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg 2017; 65: 234–245.

Authors: Antonopoulos CN, Mylonas SN, Moulakakis KG, Sergentanis TN, Sfyroeras GS, Lazaris AM et al.

Scientific Surgery

Primary stenting of the superficial femoral artery in intermittent claudication improves health related quality of life, ABI and walking distance: 12 month results of a controlled randomised multicenter trial. Eur J Vasc Endovasc Surg 2017; 53: 686-694.

Authors: Lindgren H, Qvarfordt P, Akesson M, Bergman S, Gottsater A, Jansson I et al.

Scientific Surgery

Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389: 1312–1322.

Authors: Nijssen EC, Rennenberg RJ , Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA et al.